|
Oncology Competitive Intelligence Leaders
Oncology Experts: A Central Source for Insights and Strategic Analysis
Featured Post
October 26, 2026
This year’s theme, "Crossing the Translational Divide: From Neurons to Novel Therapies," closely mirrors our commitment to evaluating breakthrough scientific data and translating it into actionable competitive...
News
ONCrg is attending SITC 2026 in Phoenix, AZ. Our dedicated Ph.D. oncology analysts will be covering key clinical sessions to analyze: 🔹 Late-breaking...
View Now Tracking Immuno-Oncoloogy at SITC 2026Webinars
Executive Summary: ONCrg analysts Kristen Cordova and Amber Mineo walk through the highest-impact lung cancer presentations from WCLC 2026 and...
View Now WCLC Insights into ESMO Signals: WebinarNews
Which mechanisms are commanding the late-breaker spotlight this year? Our analysts crunched the numbers across all LBAs: ADCs lead the field — nearly...
View Now The 2026 ESMO LBA Landscape: VisualizedNews
Our oncology experts will be on the ground, analyzing the latest practice-changing clinical data, trial results, and emerging scientific insights as...
View Now Oncology Resource Group is attending ESMO 2026News
Join our team as we break down the major readouts shaping thoracic oncology, including: 1L EGFR ex20ins+ NSCLC: First Phase III data for zipalertinib...
View Now ONCrg Live Event: WCLC Insights into ESMO SignalsNews
The ONCrg team will be on the ground September 16–17 to connect with competitive intelligence and commercial strategy leaders. Whether you're looking...
View Now Heading to Newark for Pharma CI 2026? So are we!News
Our team will be tracking the latest breakthroughs and clinical updates shaping thoracic oncology. Planning your conference coverage or need...
View Now ONCrg is heading to WCLC 2026!Webinars
Executive Summary: ONCrg analysts Robert Williams and Amanda Cook preview the highest-impact clinical presentations at ASCO 2026 across pancreatic...
View Now ASCO 2026 Analyst Briefing: WebinarWhite Papers
Potential game changers: Late-stage readouts at ASCO/EHA: Selinexor: The last of the wave of novel MOA + ruxolitinib pivotal trials in frontline...
View Now ONCrg Congress Insights: MPNs at ASCO/EHA 2026 and Beyond
